Friday 6 November 2026
Export AMGN’s income statement to Excel — free account
Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
461.71
1.43
+0.31%
Follow AMGN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 8 | 8 |
| 106.10% | 101.32% | 91.47% | 78.35% | ||
| 8.45% | 8.58% | 9.53% | 10.09% | ||
ROIC |
10.48% | 12.12% | 12.98% | 14.29% | |
Return on Tangible Assets |
67.16% | 52.93% | 48.56% | 46.92% | |
Average Days of Receivables |
95.05 | 89.61 | 97.99 | 97.14 | |
Free Cash Flow per Share |
15.06 | 15.92 | 18.84 | 17.71 | |
Free Cash Flow |
8,100.00 | 8,597.00 | 10,175.00 | 9,581.00 | |
Capital Expenditures |
(1,858.00) | (2,159.00) | (2,303.00) | (2,454.00) | |
| Other line items | |||||
Cash ROIC |
11.19% | 10.94% | 12.26% | 11.75% | |
Accounts Receivable Turnover |
4.50 | 4.31 | 4.03 | 4.13 | |
Accounts Payable Turnover |
5.63 | 4.42 | 3.95 | 0.96 | |
Inventory Turnover |
1.82 | 1.83 | 1.81 | 1.78 | |
Average Days of Payables |
71.77 | 90.69 | 90.05 | 671.79 | |
Days of Inventory on Hand |
188.76 | 191.14 | 195.50 | 206.02 | |
Tax Rate |
(0.14) | (0.14) | (0.15) | (0.15) | |
Research and Development Expense of Revenue |
19.79% | 20.16% | 20.03% | 20.15% | |
Selling, General and Administrative Expense of Revenue |
19.18% | 18.71% | 18.42% | 17.94% | |
Share Based Compensation of Revenue |
1.34% | 1.30% | 1.29% | 1.27% | |
Interest Coverage |
3.30 | 3.93 | 4.28 | 4.78 | |
Operating CF/Net income |
1.29 | 1.38 | 1.43 | 1.28 | |
Depreciation/Fixed assets |
0.80 | 0.64 | 0.59 | 0.00 | |
Capex/Depreciation |
(0.29) | (0.41) | (0.45) | 0.00 | |
Revenue per Share |
68.31 | 68.93 | 70.55 | 71.91 | |
Operating CF per Share |
18.51 | 19.92 | 23.11 | 22.25 | |
Capex per Share |
(3.45) | (4.00) | (4.26) | (4.54) | |
Capex to Sales |
0.05 | 0.06 | 0.06 | 0.06 |
Columns are period end dates · fundamentals updated 5 Nov 2026